COX-2 inhibitors, such as celecoxib, reduce tumor growth in breast cancers (103), indicating the need for further study to determine whether inhibition of these downstream components affects leptin-induced angiogenesis in a breast cancer context. The gene discussed is LEP; the disease is breast carcinoma.